#APLs

Matt

MattBiotech

For Issue #4 of my newsletter, I wrote everything in my brain on Geographic Atrophy. $APLS $ISEE $CBIO $GMTX. C3 vs. C5 vs CFH. Monthly vs. every other month. Square

Pharm. D

Pharmdca

$FSDC a potential game changer in Age-Related Macular Degeneration (GA). 2 types of AMD: Wet and Dry AMD. Dry AMD affects roughly 80-90% of individuals with AMD. The Wet AMD

pathdoc3

pathdoc3

#COVID19 - repeated trends:-Endothelium-Vitamin D deficiency-Lymphopenia-Neutrophil Extracellular Traps #NETs -Autoantibodies / Antiphospholipid Antibodies #aPLs -Lupus-like autoimmune response -Immunothrombosis - blood clots-#ME/CFS / Dysa

Sentiv

sentivcapital

$FSDC (thread): Merger with Gemini in January. Focused on huge GA/dAMD market (think multiples of wAMD). No current Tx, $APLS C3 first to market, with other C inhibitors to follow

brendan

brendan_49

Basic view/strat on various stocks:$OCUL - big weight, riding indefinitely.$REPL - ditto. I believe in vision of OV's as backbone PD1 combo.$FGEN - bullish on US regulatory outcome, bullish on

Hillel

hillelogram

This is an interesting question, and while I reject the argument that FP is "better" than OOP I think it's worth discussing complex forces at play here. First of all,

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.